Endotoxemia Clinical Trial
Official title:
The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia.
During sepsis and septic shock the immune response can be overwhelming leading to excessive tissue damage, organ failure and death. Ideally, the inflammatory response is modulated leading to both adequate protection to invading pathogens as well as limitation of an exuberant immune response. In the last few years adenosine is proposed to have a central role in the modulation of inflammation. In unfavorable conditions such as hypoxia, ischemia or inflammation adenosine is quickly up-regulated; with concentrations up to tenfold in septic patients. Many animal studies have shown that adenosine is able to attenuate the inflammatory response and decrease mortality rates. Therefore, pharmacological elevation of the adenosine concentration is an potential target to attenuate inflammation and limit organ injury. Dipyridamole, an adenosine re-uptake inhibitor is able to increase the adenosine concentration and limit ischemia-reperfusion injury. In order to study the effects of dipyridamole on the inflammatory response we aim to use the so called human endotoxemia model. This model permits elucidation of key players in the immune response to a gram negative stimulus in vivo, therefore serving as a useful tool to investigate potential novel therapeutic strategies in a standardized setting.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT02922673 -
The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia
|
N/A | |
Completed |
NCT01766414 -
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II
|
Phase 3 | |
Completed |
NCT04130321 -
Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans
|
N/A | |
Completed |
NCT02612480 -
Ticagrelor in Human Endotoxemia Response to Human Endotoxemia
|
N/A | |
Completed |
NCT01474629 -
Probiotic Sport Study
|
N/A | |
Completed |
NCT00246714 -
Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans
|
Phase 1 | |
Recruiting |
NCT06147440 -
Different Dietary Patterns
|
N/A | |
Recruiting |
NCT03901807 -
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
|
N/A | |
Completed |
NCT03754504 -
Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03800277 -
Effect of Cranberry and Agaves Extract on Microbiota and Intestinal Health
|
N/A | |
Completed |
NCT00785018 -
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia
|
N/A | |
Recruiting |
NCT00413348 -
Type 2 Diabetes and the Effect of Probiotics
|
N/A | |
Recruiting |
NCT00413465 -
Study of Renal Blood Flow During Human Endotoxemia
|
N/A | |
Completed |
NCT00412906 -
Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls
|
N/A | |
Completed |
NCT05752968 -
Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease
|
||
Completed |
NCT01374711 -
The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia
|
N/A | |
Completed |
NCT00916448 -
The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia
|
N/A | |
Completed |
NCT00332267 -
Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia
|
N/A | |
Completed |
NCT03482284 -
Effect of Monosaccharides on Intestinal Barrier Function
|
N/A |